Carter Gould
Stock Analyst at Cantor Fitzgerald
Total Price Targets
37
Stocks Covered
14
Sectors
Healthcare, Technology
Most Recent
Feb 2, 2026
Notable Calls (Last 12 Months)
Most Bullish
Stocks Covered by Carter Gould
| Symbol | Company | Latest Target | Current Price | Upside | # Targets | Last Updated |
|---|---|---|---|---|---|---|
| REGN | Regeneron Pharmaceuticals, Inc. | $800.00 | $703.72 | +13.7% | 5 | Feb 2, 2026 |
| VRTX | Vertex Pharmaceuticals Incorporated | $485.00 | $425.06 | +14.1% | 1 | Nov 4, 2025 |
| GILD | Gilead Sciences, Inc. | $135.00 | $132.04 | +2.2% | 3 | Oct 9, 2025 |
| ABBV | AbbVie Inc. | $245.00 | $206.29 | +18.8% | 4 | Sep 15, 2025 |
| LLY | Eli Lilly and Company | $825.00 | $961.67 | -14.2% | 2 | Aug 13, 2025 |
| CRM | Salesforce, Inc. | $210.00 | $184.04 | +14.1% | 1 | Apr 23, 2025 |
| PFE | Pfizer Inc. | $24.00 | $26.38 | -9.0% | 4 | Apr 22, 2025 |
| AMGN | Amgen Inc. | $315.00 | $328.69 | -4.2% | 4 | Oct 7, 2024 |
| MRK | Merck & Co., Inc. | $140.00 | $111.89 | +25.1% | 3 | Oct 7, 2024 |
| TVTX | Travere Therapeutics, Inc. | $18.00 | $44.19 | -59.3% | 1 | Oct 1, 2024 |
| NBIX | Neurocrine Biosciences, Inc. | $160.00 | $131.64 | +21.5% | 2 | Sep 9, 2024 |
| BMY | Bristol-Myers Squibb Company | $41.00 | $58.22 | -29.6% | 2 | Jul 29, 2024 |
| CYTK | Cytokinetics, Incorporated | $95.00 | $64.40 | +47.5% | 2 | May 23, 2024 |
| BIIB | Biogen Inc. | $215.00 | $186.69 | +15.2% | 3 | Apr 3, 2024 |
Recent Activity
- Feb 2, 2026— Set$800.00price target onREGN(Regeneron Pharmaceuticals, Inc.)
- Nov 4, 2025— Set$485.00price target onVRTX(Vertex Pharmaceuticals Incorporated)
- Oct 29, 2025— Set$740.00price target onREGN(Regeneron Pharmaceuticals, Inc.)
- Oct 9, 2025— Set$135.00price target onGILD(Gilead Sciences, Inc.)
- Sep 15, 2025— Set$245.00price target onABBV(AbbVie Inc.)
- Aug 13, 2025— Set$825.00price target onLLY(Eli Lilly and Company)
- Apr 23, 2025— Set$210.00price target onCRM(Salesforce, Inc.)
- Apr 22, 2025— Set$24.00price target onPFE(Pfizer Inc.)
- Apr 22, 2025— Set$695.00price target onREGN(Regeneron Pharmaceuticals, Inc.)
- Apr 22, 2025— Set$125.00price target onGILD(Gilead Sciences, Inc.)
- Oct 7, 2024— Set$140.00price target onMRK(Merck & Co., Inc.)
- Oct 7, 2024— Set$315.00price target onAMGN(Amgen Inc.)
- Oct 1, 2024— Set$18.00price target onTVTX(Travere Therapeutics, Inc.)
- Sep 25, 2024— Set$32.00price target onPFE(Pfizer Inc.)
- Sep 9, 2024— Set$160.00price target onNBIX(Neurocrine Biosciences, Inc.)
- Jul 29, 2024— Set$41.00price target onBMY(Bristol-Myers Squibb Company)
- Jul 10, 2024— Set$30.00price target onPFE(Pfizer Inc.)
- May 23, 2024— Set$95.00price target onCYTK(Cytokinetics, Incorporated)
- May 3, 2024— Set$300.00price target onAMGN(Amgen Inc.)
- Apr 3, 2024— Set$215.00price target onBIIB(Biogen Inc.)
Frequently Asked Questions
Who is Carter Gould?
Carter Gould is a stock analyst at Cantor Fitzgerald covering 14 stocks primarily in Healthcare, Technology. They have issued 37 price targets since Oct 28, 2021.
What stocks does Carter Gould cover?
Carter Gould currently covers 14 stocks, including REGN, ABBV, PFE, AMGN, GILD.
What is Carter Gould's latest price target?
Carter Gould's most recent price target was $800.00 on REGN (Regeneron Pharmaceuticals, Inc.), set on Feb 2, 2026.
What is Carter Gould's highest price target?
Carter Gould's highest issued price target is $825.00 on LLY, set on Aug 13, 2025.
More Analysts at Cantor Fitzgerald
Coverage based on publicly published price targets. Not investment advice.